Detalles de la búsqueda
1.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Front Immunol
; 14: 1259725, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37928549
2.
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Vaccines (Basel)
; 11(10)2023 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37896937
3.
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.
Front Immunol
; 14: 1129245, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37063833
4.
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Front Immunol
; 14: 1228461, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37600800
5.
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
Front Immunol
; 13: 822159, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35281053
6.
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
Emerg Microbes Infect
; 11(1): 2229-2247, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031930
7.
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus.
Front Immunol
; 13: 1023164, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36466896
8.
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants.
Vaccines (Basel)
; 9(7)2021 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34358195
Resultados
1 -
8
de 8
1
Próxima >
>>